BioCentury
ARTICLE | Company News

Kite looks to Gadeta for gamma delta T cell tech

July 20, 2018 5:58 PM UTC

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences Inc. (NASDAQ:GILD), will obtain an undisclosed upfront equity purchase in Gadeta and will have an exclusive option to acquire the company.

According to BioCentury's BCIQ database, the deal is the first disclosed for Gilead in the gamma delta space. Gilead is at least the second large biopharma to acquire a stake in a smaller biotech developing gamma delta T cell-based therapies...